Navigation Links
New target for Alzheimer's disease identified
Date:5/7/2008

SAN FRANCISCO, CA May 7, 2008 ---Alzheimers disease (AD) is an incurable disease that is increasing in prevalence and will increase even more rapidly as the Baby Boom generation enters the age of highest risk. The available AD drugs are only partially effective in some patients. New strategies are urgently needed.

In a new study, published in todays Journal of Neuroscience, researchers in the laboratory of Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease (GIND), have determined in mouse models that modulating the activity of enkephalin peptides in the brain might reduce the cognitive deficits seen in Alzheimers disease.

Enkephalins are part of the endogenous opioid system, which modulates learning and memory and other brain functions. They are produced by several different cell types in the brain, particularly in areas affected by AD. Enkephalins are derived by enzymatic cleavage from a precursor protein, preproenkephalin, and stored in vesicles. Upon stimulation, enkephalins are released with neurotransmitters, such as glutamate.

The enkephalin pathway is an intriguing candidate for us because it is involved in many functions that are affected by Alzheimers and other neurodegenerative diseases, said Dr. Mucke. We were not sure, though, whether it contributed causally to the disease or acts as a compensatory mechanism.

To better understand the activities of the enkephalins in AD, the Mucke team examined their functions in a transgenic mouse model of AD. These mice express two proteins associated with ADhuman amyloid precursor protein (hAPP) and its cleavage product, A peptidesin neurons and exhibit several characteristics of AD.

The team found increased levels of preproenkephalin mRNA and of enkephalin in brain regions important for memory that are affected in early stages of AD.

When they genetically manipulated the mice to make them more or less susceptible to neuronal damage, the scientists found that the enkephalin levels were also affected. Furthermore, as levels of the enkephalins increased, the ability of mice to complete behavioral tests declined. Compounds that blocked opioid receptors, through which enkaphalins exert their effects, reduced cognitive deficits. AD patients also showed increased levels of enkephalins in brain regions affected by the disease.

Our results indicate that the high levels of enkephalins may contribute to cognitive impairments in hAPP mice and maybe also in AD patients, said Dr. Mucke. Although these are early results, they are encouraging and may lead the way to a new AD therapy based on limiting enkephalin production or signaling.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related medicine news :

1. Symposium Targets Critical Manufacturing Topics for Emerging Growth Companies
2. New Targets Found That Stop Tumor Growth
3. Analysis of alcoholics brains suggests treatment target
4. Study raises questions about prostate cancer therapies targeting IGF-1
5. Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
6. New Independent Research Firm Targets Firms with Little or No Analyst Following
7. New lymphoma therapies targets diverse and difficult cancer
8. Researchers identify new cell targets for preventing growth of breast and other tumors
9. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
10. China Medical Technologies to Announce 4QFY2007 Financial Results, Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008
11. Mayo Clinic identifies treatment target for liver cancer recurrence and survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 2017 , ... CareAcademy, a provider of specialized online training ... in seed funding to further expand its course portfolio and increase its market ... the company’s primary investors. , Founded in 2016, CareAcademy currently serves ...
(Date:8/17/2017)... ... August 17, 2017 , ... Pot Valet is a leading provider of ... city in the state, and soon, every state in the country, the company offers ... a cannabis dispensary altogether. , According to Pot Valet, all California patients ...
(Date:8/17/2017)... ... ... Media, the industry leader in digital marketing for medical practices, has been recognized as one ... the Inc. 5000 for the second time in two years. Shawn Miele, Chief Executive Officer ... for the second year in a row. It’s extremely difficult to make this list once. ...
(Date:8/17/2017)... ... August 17, 2017 , ... Finalists in the 2017 ... announced today. The awards recognize the world’s best employers and the human resources ... drive great places to work. , A diverse group of organizations and individuals ...
(Date:8/17/2017)... WA and Lighthouse Point, FL (PRWEB) , ... ... ... healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology business ... examined patient care data to quantify the dollar amount of attributable savings from ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), ... in Lakewood, Colorado . The reputable clinic ... Lipkin , PT, DPT with his staff of four clinicians. ... of Pittsburgh and brings over 10 years of experience with ... Belmar PT marks the 10th PRN clinic in and ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
Breaking Medicine Technology: